Actuate Therapeutics, a clinical-stage biotech focused on elraglusib — a proprietary GSK-3β inhibitor — continues to demonstrate promising Phase 2 data in metastatic pancreatic ductal adenocarcinoma (mPDAC) following treatment of over 500 patients. However, the firm’s financials reflect persistent operating losses, underscoring capital demands for advancing clinical development. Its strategy relies heavily on external contracts and intellectual property protection, navigating competitive oncology dynamics. Upcoming oral formulation trials represent critical near-term catalysts contingent upon financing.